(0)
Funding to Accelerate Hiring as Outcomes4Me Diversifies Cancer Support and Expands to Empower Patients in Europe
CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ Outcomes4Me Inc., developer of an Artificial Intelligence (AI)-powered platform to empower cancer patients to navigate their care, today announced it has raised $12 million in an oversubscribed Series A round. Funds will be used to extend Outcomes4Me s platform beyond breast cancer to other cancers, grow the platform s regulatory-grade dataset, and expand to more patients in Europe.
The round was led by Northpond Ventures, with participation from all existing investors, including Sierra Ventures, Asset Management Ventures, Merstal Ltd, IRA Capital, and others. Andrea Jackson, a Northpond Ventures Director, will join Outcomes4Me s board.
Jefferson: San Antonio tourism is bouncing back, and that s good news for Ron Nirenberg
expressnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from expressnews.com Daily Mail and Mail on Sunday newspapers.
Charlyn Fargo Ware: What Healthy Eating Means Now
noozhawk.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from noozhawk.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, and welcome to the Seagen fourth-quarter and full-year 2020 financial results conference call. [Operator instructions] Please note that this event is being recorded. I would now like to turn the conference over to Ms. Peggy Pinkston, vice president of investor relations.
Please go ahead.
Vice President of Investor Relations
Thank you, operator, and good afternoon, everyone. I d like to welcome all of you to Seagen s fourth-quarter and full-year 2020 financial results conference call. This afternoon, we issued a press release with our results and that press release and supporting slides are available on our website in the investors section, events and presentations page. Speakers on our call today will be Clay Siegall, president and chief executive officer; Chip Romp, executive vice president, commercial U.S.; Todd Simpson, chief financial officer; and Roger Dansey, chief medical officer.
By oracknows on August 26, 2015.
It s always disappointing to see a good journal fall for bad medicine, particularly when it s in your field. For example, the Journal of Clinical Oncology (affectionately referred to by its abbreviation JCO) is the official journal of the American Society of Clinical Oncology (ASCO) and probably the most read clinical journal by those involved in the clinical care of cancer patients. Just as most oncologists, surgeons, and radiation oncologists who specialize in the care of cancer patients belong to ASCO, most of them also at least peruse JCO on a regular basis because major results of large cooperative group trials are often published there. Basically, everyone wants to publish his oncology clinical trial in JCO. Getting into